STOCK TITAN

vTv Therapeutics (VTVT) SEC Filings

VTVT NASDAQ

vTv Therapeutics Inc. filings document the regulatory record of a Nasdaq-listed, late-stage biopharmaceutical company developing oral small-molecule candidates for diabetes and other chronic diseases. Form 8-K reports cover financial results, Regulation FD investor presentations, material agreements, and clinical or regulatory disclosures tied to cadisegliatin and other pipeline assets.

The company’s filings also disclose licensing arrangements involving vTv Therapeutics LLC and HPP737, capital-structure and security-related matters, and governance information in proxy materials. Definitive proxy statements describe board matters, executive compensation, equity awards, shareholder voting items, and related corporate-governance disclosures.

Rhea-AI Summary

At vTv Therapeutics Inc. (VTVT), reporting person Samsara BioCapital, L.P. sold 61,287 shares of Class A common stock at $17.60 per share in a block trade on November 12, 2026. The shares were held for the exclusive benefit of limited partners who had redeemed their interests in Samsara LP; Samsara BioCapital GP, LLC and Srinivas Akkaraju had no economic interest in them.

Srinivas Akkaraju reported beneficial ownership of 412,654 shares, or 9.9%, with the percentage rounded down. The calculation used 4,011,465 shares outstanding as of November 5, 2026, and gave effect to warrants and options exercisable within 60 days, including 6,399 stock options. Warrant exercises are subject to a 9.99% beneficial ownership blocker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
ownership
-
Rhea-AI Summary

vTv Therapeutics Inc. (VTVT) is the issuer in a notice listing a proposed sale by shareholder Samsara BioCapital, L.P. of 61,287 common shares, with an aggregate market value of $1,315,831.89 and an approximate sale date of November 12, 2026. Merrill Lynch is listed as broker. The notice lists 4,011,465 common shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
other
-
Rhea-AI Summary

vTv Therapeutics Inc. reported $36.8 million of revenue for the nine months ended September 30, 2026, compared with none in 2025. Revenue included a $20.0 million Newsoara upfront fee and $16.9 million of G42 license revenue recognized after the related intellectual property transfer. Net loss attributable to vTv was $540,000, versus $19.836 million a year earlier, while net cash used in operating activities was $12.477 million, compared with $16.004 million. Research and development expense increased 81.2% to $25.3 million.

Cash and cash equivalents were $77.2 million as of September 30, 2026, and the company said additional capital will be needed as it expects continued losses and negative operating cash flow. The Phase 3 CATT1 study completed enrollment with 166 patients randomized; topline results are expected in mid-2027. A Phase 2a pilot for people with type 1 diabetes using hybrid closed-loop insulin delivery systems randomized its first participant on October 27, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
quarterly report
Rhea-AI Summary

vTv Therapeutics Inc. completed enrollment in its Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes, with 166 participants randomized to cadisegliatin 800 mg once daily, cadisegliatin 800 mg twice daily, or placebo over six months. The primary endpoint measures level 2 and level 3 hypoglycemic events; topline results are expected in mid 2027. The company also randomized the first participant in its Phase 2a Hybrid CATT1 study of people using hybrid closed-loop insulin systems.

Cash and cash equivalents were $77.2 million as of September 30, 2026, compared with $88.9 million as of December 31, 2025; vTv expects cash to fund operations well through the anticipated CATT1 readout. Third-quarter R&D expenses were $7.5 million and G&A expenses were $4.9 million, versus $7.0 million and $3.7 million a year earlier. Net loss attributable to vTv shareholders was $11.6 million, compared with $8.7 million. Revenue for the nine months ended September 30, 2026, was $36.839 million, versus $0 in 2025. The FDA granted Orphan Drug Designation to HPPD, an investigational candidate for sickle cell disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
current report
-
Rhea-AI Summary

For vTv Therapeutics Inc. (VTVT), Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over Class A common stock. Integrated Core Strategies reports 312,138 shares, or 7.9%; each of the other three reporting persons reports 342,481 shares, or 8.7%. The report states that securities potentially beneficially owned by Millennium Management, Millennium Group Management and Mr. Englander are held by entities subject to voting control and investment discretion of the identified managers and Mr. Englander. It also says the disclosure should not, in and of itself, be construed as an admission by those reporting persons of beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
ownership
-
Rhea-AI Summary

vTv Therapeutics Inc. adopted its Third Amended and Restated By-Laws on October 1, 2026, changing director-nomination procedures, stockholder voting rules and the forum for certain lawsuits. A stockholder seeking to nominate directors must deliver reasonable evidence of compliance with Rule 14a-19 no later than five business days before the meeting. For matters other than director elections, the standard is approval by a majority of the voting power of shares cast affirmatively or negatively, subject to the company’s certificate of incorporation, bylaws, applicable law and exchange rules. Federal district courts are the exclusive forum for complaints asserting claims under the Securities Act of 1933, unless vTv consents in writing to another forum. Other revisions align meeting procedures with the Delaware General Corporation Law and make ministerial and conforming changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
current report
Rhea-AI Summary

vTv Therapeutics Inc. reported $36.8 million in collaboration and license revenue for the six months ended June 30, 2026, driven by a $20.0 million upfront payment from Newsoara and $16.9 million of license revenue recognized upon lifting IP restrictions for its G42 collaboration. This produced operating income of $9.3 million and net income of $11.1 million, compared with a loss a year earlier, although the company still carries an accumulated deficit of $315.6 million.

Research and development spending rose sharply to $17.7 million in the first half, largely to advance cadisegliatin, its Phase 3 oral adjunctive therapy for type 1 diabetes, and supporting studies. Cash and cash equivalents were $86.6 million at June 30, 2026, with net cash used in operating activities of $2.3 million. Management states it expects continued operating losses tied to ongoing trials and anticipates needing substantial additional capital over time despite the recent non-recurring license inflows.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
quarterly report
-
Rhea-AI Summary

vTv Therapeutics reported second quarter 2026 results and updates on its type 1 diabetes program. For the three months ended June 30, 2026, the company recorded a net loss attributable to shareholders of $13.1 million, or $(1.05) per basic and diluted share, with R&D expenses of $8.8 million and G&A expenses of $5.2 million. No revenue was recognized in the quarter.

For the six months ended June 30, 2026, vTv reported revenue of $36,839 (in thousands) and net income attributable to vTv of 11,080 (in thousands), compared with no revenue and a net loss in the prior-year period. Cash and cash equivalents were $86,643 (in thousands) as of June 30, 2026, and the company expects its cash to fund operations through the anticipated topline data readout from the Phase 3 CATT1 trial of cadisegliatin. Enrollment in CATT1 is expected to complete in the third quarter of 2026, a Phase 2a Hybrid CATT1 trial is planned to start before year end 2026, and a Key Opinion Leader event on cadisegliatin and type 1 diabetes is planned for the fourth quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
current report
-
Rhea-AI Summary

vTv Therapeutics Inc. is the subject of an amended Schedule 13G filing reporting beneficial ownership of its Class A common stock by several Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 249,027 shares of Class A common stock, representing 6.3% of the class, all with shared voting and dispositive power.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 269,874 shares, representing 6.9% of the Class A common stock, with shared voting and dispositive power and no sole voting or dispositive power. The filing explains that securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and it states that this structure is not, by itself, an admission of beneficial ownership. A joint filing agreement among the reporting persons is included as an exhibit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
ownership
Rhea-AI Summary

BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.

vTv Therapeutics Inc. reported that director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options exercisable into Class A common stock at $35.08 per share. The options vest on the earlier of June 26, 2027 or the 2027 annual shareholder meeting and expire on June 26, 2036.

According to the disclosure, the options were granted to Dr. Cheong in his capacity as a director, but the grant is reported for Baker Bros.–affiliated funds because they hold an indirect proportionate pecuniary interest. The adviser to the funds holds voting and dispositive power over the options and any resulting shares, while Dr. Cheong does not retain compensation rights under adviser policies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.80%
Tags
insider

FAQ

How many vTv Therapeutics (VTVT) SEC filings are available on StockTitan?

StockTitan tracks 43 SEC filings for vTv Therapeutics (VTVT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for vTv Therapeutics (VTVT)?

The most recent SEC filing for vTv Therapeutics (VTVT) was filed on November 16, 2026.